To model ER+ BC, we used the established ER+ cell lines MCF-7 and T47D (Tables 1) and 2 ER+PR+HER2− PDXs: T99 derived from an untreated primary tumor and METS15 derived from the ascites of a patient with advanced disease (Table 2). This evidence concerns the gene ERBB2 and breast cancer.